Display options
Cite
Narducci DM, Diamond AB, Bernhardt DT, et al. COVID Vaccination in Athletes and Updated Interim Guidance on the Preparticipation Physical Examination During the SARS-Cov-2 Pandemic. Clin J Sport Med. 2022;32(1):e1-e6doi: 10.1097/JSM.0000000000000981.
Narducci, D. M., Diamond, A. B., Bernhardt, D. T., & Roberts, W. O. (2022). COVID Vaccination in Athletes and Updated Interim Guidance on the Preparticipation Physical Examination During the SARS-Cov-2 Pandemic. Clinical journal of sport medicine : official journal of the Canadian Academy of Sport Medicine, 32(1), e1-e6. https://doi.org/10.1097/JSM.0000000000000981
Narducci, Dusty Marie, et al. "COVID Vaccination in Athletes and Updated Interim Guidance on the Preparticipation Physical Examination During the SARS-Cov-2 Pandemic." Clinical journal of sport medicine : official journal of the Canadian Academy of Sport Medicine vol. 32,1 (2022): e1-e6. doi: https://doi.org/10.1097/JSM.0000000000000981
Narducci DM, Diamond AB, Bernhardt DT, Roberts WO. COVID Vaccination in Athletes and Updated Interim Guidance on the Preparticipation Physical Examination During the SARS-Cov-2 Pandemic. Clin J Sport Med. 2022 Jan 01;32(1):e1-e6. doi: 10.1097/JSM.0000000000000981. PMID: 34723865.
Copy Download .nbib Format: NLM
Share it on

Clin J Sport Med. 2022 Jan 01;32(1):e1-e6. doi: 10.1097/JSM.0000000000000981.

COVID Vaccination in Athletes and Updated Interim Guidance on the Preparticipation Physical Examination During the SARS-Cov-2 Pandemic.

Clinical journal of sport medicine : official journal of the Canadian Academy of Sport Medicine

Dusty Marie Narducci, Alex B Diamond, David T Bernhardt, William O Roberts

Affiliations

  1. Departments of Family Medicine and Orthopedics, University of South Florida, Tampa, Florida.
  2. Departments of Pediatrics and Orthopedics and Rehabilitation, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin; and.
  3. Department of Family Medicine and Community Health, University of Minnesota Medical School, Minneapolis, Minnesota.

PMID: 34723865 DOI: 10.1097/JSM.0000000000000981

Abstract

ABSTRACT: The American Medical Society for Sports Medicine (AMSSM) convened an expert panel to address the current evidence, knowledge gaps, and recommendations surrounding the COVID vaccination in athletes during the SARS-CoV-2 pandemic. The group held a series of meetings beginning in July 2021 and reviewed the available literature while using an iterative process and expert consensus to finalize this guidance statement. This document is intended to provide clinicians with suggestions on how to incorporate the COVID vaccination during the preparticipation physical examination for athletes in all levels of training and competition. The statement is not intended to address treatment, infection control principles, safety, ethical discussion, or public health issues related to SARS-CoV-2. The AMSSM task force acknowledges the clinical uncertainty, evolving public health objectives, and the limited data currently available to create this guidance statement.

Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.

Conflict of interest statement

The authors report no conflicts of interest.

References

  1. World Health Organization. Director-General's remarks at the media briefing on 2019-nCoV on 11 February 2020. Available at: http://www.who.int/dg/speeches/detail/who-director-general-s-remarks-at-the-media-briefing-on-2019-ncov-on-11-february-2020. Accessed February 12, 2020. - PubMed
  2. Lin JT, Zhang JS, Su N, et al. Safety and immunogenicity from a phase I trial of inactivated severe acute respiratory syndrome coronavirus vaccine. Antivir Ther. 2007;12:1107–1113. - PubMed
  3. Martin JE, Louder MK, Holman LA, et al. A SARS DNA vaccine induces neutralizing antibody and cellular immune responses in healthy adults in a Phase I clinical trial. Vaccine. 2008;26:6338–6343. - PubMed
  4. The College of Physicians of Philadelphia. The history of vaccines: vaccine development, testing, and regulation. Available at: https://www.historyofvaccines.org/content/articles/vaccine-development-testing-and-regulation. Accessed October 20, 2020. - PubMed
  5. US Food & Drug Administration.Emergency use authorization (EUA) of the Pfizer-Biontech covid-19 vaccine to prevent coronavirus disease 2019 (covid-19). Available at: https://www.fda.gov/media/144413/download. Accessed December 29, 2020. - PubMed
  6. US Food & Drug Administration. Emergency use authorization (EUA) of the Moderna covid-19 vaccine to prevent coronavirus disease 2019 (covid-19) US Food & Drug Administration. Available at: https://www.fda.gov/media/144637/download?utm_medium=email&utm_source=govdelivery. Accessed December 18, 2020. - PubMed
  7. US Food & Drug Administration. Emergency use authorization (EUA) of the Janssen covid-19 vaccine to prevent coronavirus disease 2019 (covid-19). Available at: https://www.fda.gov/media/146304/download. Accessed March 1, 2021. - PubMed
  8. World Health Organization. DRAFT landscape of COVID-19 candidate vaccines – 11 April 2020. Available at: https://www.who.int/blueprint/priority-diseases/key-action/Novel_Coronavirus_Landscape_nCoV_11April2020.PDF?ua=1. Accessed October 20, 2020. - PubMed
  9. Kaur SP, Gupta V. COVID-19 Vaccine: a comprehensive status report. Virus Res. 2020;288:198114. - PubMed
  10. Krammer F. SARS-CoV-2 vaccines in development. Nature. 2020;586:516–527. - PubMed
  11. Borobia AM, Carcas AJ, Pérez-Olmeda M, et al. Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial. Lancet. 2021;398:121–130. - PubMed
  12. Centers for Disease Control and Prevention. Interim clinical considerations for use of COVID-19 vaccines currently authorized in the United States. Available at: https://www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-us.html. Accessed July 23, 2021. - PubMed
  13. Normark J, Vikström L, Gwon YD, et al. Heterologous ChAdOx1 nCoV-19 and mRNA-1273 vaccination. N Engl J Med. 2021;385:1049–1051. - PubMed
  14. Shaw RH, Stuart A, Greenland M, et al. Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data. Lancet. 2021;397:2043–2046. - PubMed
  15. Centers for Disease Control and Prevention. COVID-19 vaccine administration - errors and deviation. Available at: https://www.cdc.gov/vaccines/covid-19/downloads/covid19-vaccine-errors-deviations.pdf. Accessed June 8, 2021. - PubMed
  16. Infectious Disease Society of America. COVID-19 prioritization of diagnostic testing. Available at: https://www.idsociety.org/globalassets/idsa/public-health/covid-19-prioritization-of-dx-testing.pdf. Accessed March 22, 2020. - PubMed
  17. Doedée AM, Boland GJ, Pennings JL, et al. Effects of prophylactic and therapeutic paracetamol treatment during vaccination on hepatitis B antibody levels in adults: two open-label, randomized controlled trials. Plos One. 2014;9:e98175. - PubMed
  18. Prymula R, Siegrist CA, Chlibek R, et al. Effect of prophylactic paracetamol administration at time of vaccination on febrile reactions and antibody responses in children: two open-label, randomised controlled trials. Lancet. 2009;374:1339–1350. - PubMed
  19. Krammer F, Srivastava K, Alshammary H, et al. Antibody responses in seropositive persons after a single dose of SARS-CoV-2 mRNA vaccine. N Engl J Med. 2021;384:1372–1374. - PubMed
  20. Manisty C, Otter AD, Treibel TA, et al. Antibody response to first BNT162b2 dose in previously SARS-CoV-2-infected individuals. Lancet. 2021;397:1057–1058. - PubMed
  21. Prendecki M, Clarke C, Brown J, et al. Effect of previous SARS-CoV-2 infection on humoral and T-cell responses to single-dose BNT162b2 vaccine. Lancet. 2021;397:1178–1181. - PubMed
  22. Centers for Disease Control and Prevention. Updated healthcare infection prevention and Control recommendations in response to COVID-19 vaccination. Available at: https://www.cdc.gov/coronavirus/2019-ncov/hcp/infection-control-after-vaccination.html. Accessed May 5, 2021. - PubMed
  23. Oliver S. Data and clinical considerations for additional doses in immunocompromised people. Presented at Advisory Committee on Immunization Practices in Atlanta, GA on Jul 22, 2021. Available at: https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2021-07/07-COVID-Oliver-508.pdf. Accessed on July 23, 2021. - PubMed
  24. Shimabukuro TT, Kim SY, Myers TR, et al. Preliminary findings of mRNA covid-19 vaccine safety in pregnant persons. N Engl J Med. 2021;384:2273–2282. - PubMed
  25. Anderson EJ, Campbell JD, Creech CB, et al. Warp speed for coronavirus disease 2019 (COVID-19) vaccines: why are children stuck in neutral?. Clin Infect Dis. 2021;73:336–340. - PubMed
  26. Centers for Disease Control and Prevention. Vaccines for children program (VFC). Available at: https://www.cdc.gov/vaccines/programs/vfc/. Accessed November 5. 2020. - PubMed
  27. Anand P, Stahel VP. Review the safety of Covid-19 mRNA vaccines: a review. Patient Saf Surg. 2021;15:20. - PubMed
  28. Cagle PJ Jr.. Shoulder injury after vaccination: a systematic review. Rev Bras Ortop (Sao Paulo). 2021;56:299–306. - PubMed
  29. Centers for Disease Control and Prevention. Syncope after vaccination—United States, January 2005-July 2007. MMWR Morb Mortal Wkly Rep. 2008;57:457–460. - PubMed
  30. Centers for Disease Control and Prevention. Vaccine safety datalink (VSD). Available at: https://www.cdc.gov/vaccinesafety/ensuringsafety/monitoring/vsd/index.html. Accessed November 5. 2020. - PubMed
  31. Chapin-Bardales J, Gee J, Myers T. Reactogenicity following receipt of mRNA-based COVID-19 vaccines. JAMA. 2021;325:2201–2202. - PubMed
  32. Drezner JA, Heinz WM, Asif IM, et al. Cardiopulmonary considerations for high school student-athletes during the COVID-19 pandemic: NFHS-AMSSM guidance statement. Sports Health. 2020;12:459–461. - PubMed
  33. Erickson CC, Salerno JC, Berger S, et al. Sudden death in the young: information for the primary care provider. Pediatrics. 2021;148:e2021052044 - PubMed
  34. Gargano JW, Wallace M, Hadler SC, et al. Use of mRNA COVID-19 vaccine after reports of myocarditis among vaccine recipients: update from the Advisory Committee on Immunization Practices—United States, June 2021. MMWR Morb Mortal Wkly Rep. 2021;70:977–982. - PubMed
  35. Jotwani V, Narducci DM. Pain in right shoulder · recent influenza vaccination · history of hypertension and myocardial infarction Dx?. J Fam Pract. 2019;68:44–46. - PubMed
  36. Kaur RJ, Dutta S, Bhardwaj P, et al. Adverse events reported from COVID-19 vaccine trials: a systematic review. Indian J Clin Biochem. 2021;36:1–13. - PubMed
  37. Majeed A, Papaluca M, Molokhia M. Assessing the long-term safety and efficacy of COVID-19 vaccines. J R Soc Med. 2021;114:337–340. - PubMed
  38. Moulson N, Petek BJ, Drezner JA, et al. SARS-CoV-2 cardiac involvement in young competitive athletes. Circulation. 2021;144:256–266. - PubMed
  39. Shahbaz M, Blanc PD, Domeracki SJ, et al. Shoulder injury related to vaccine administration (SIRVA): an occupational case report. Workplace Health Saf. 2019;67:501–505. - PubMed
  40. Shay DK, Shimabukuro TT, DeStefano F. Myocarditis occurring after immunization with mRNA-based COVID-19 vaccines. JAMA Cardiol. 2021;6:1115–1117. - PubMed
  41. Valenzuela PL, Simpson RJ, Castillo-García A, et al. Physical activity: a coadjuvant treatment to COVID-19 vaccination Brain Behav Immun. 2021;94:1–3. - PubMed
  42. Waninger KN, Slenker N. Frozen shoulder related to influenza vaccine administration. Clin J Sport Med. 2021 [epub ahead of print]. - PubMed
  43. Bernhardt DT, Roberts WO. PPE Preparticiption Physical Examination. IL: American Academy of Pediatrics. Itasca; 2019. - PubMed
  44. Singer ME, Taub IB, Kaleber DC. Risk of myocarditis from COVID-19 infection in people under age 20: a population-based analysis. medRxiv—The Preprint Server for Health Science, 2021. - PubMed
  45. CDC COVID-19 Vaccine Breakthrough Case Investigations Team. COVID-19 vaccine breakthrough infections reported to CDC—United States, January 1-April 30, 2021. MMWR Morb Mortal Wkly Rep. 2021;70:792–793. - PubMed
  46. Daly M, Jones A, Robinson E. Public trust and willingness to vaccinate against COVID-19 in the US from October 14, 2020, to March 29, 2021. JAMA. 2021;325:2397–2399. - PubMed
  47. Hull JH, Schwellnus MP, Pyne DB, Shah A. COVID-19 vaccination in athletes: ready, set, go. Lancet Respir Med. 2021;9:455–456. - PubMed
  48. Kaplan RM, Milstein A. Influence of a COVID-19 vaccine's effectiveness and safety profile on vaccination acceikptance. Proc Natl Acad Sci USA. 2021;118:e2021726118. - PubMed
  49. Meyer T, Wolfarth B, Gärtner B. Recommendations for athletes to vaccinate against SARS-CoV-2. Deutsche Z für Sportmedizin/German J Sports Med. 2021;72:E1–E4. - PubMed
  50. Nguyen KH, Srivastav A, Razzaghi H, et al. COVID-19 vaccination intent, perceptions, and reasons for not vaccinating among groups prioritized for early vaccination—United States, September and December 2020. MMWR Morb Mortal Wkly Rep. 2021;70:217–222. - PubMed
  51. Centers for Disease Control and Prevention. Communication resources. Available at: https://www.cdc.gov/coronavirus/2019-ncov/communication/index.html. Accessed June 8, 2021. - PubMed

Publication Types